Compare Stocks → The new financial threat that could wipe out millions… (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ANNXNASDAQ:BMEANASDAQ:CRBPNASDAQ:ESPR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$4.87+3.0%$5.60$1.57▼$8.40$443.85M1.291.57 million shs1.62 million shsBMEABiomea Fusion$11.07-7.8%$13.99$8.13▼$43.69$397.86M-0.33952,577 shs667,374 shsCRBPCorbus Pharmaceuticals$42.39+6.6%$38.31$3.03▼$49.87$445.52M2.46722,211 shs779,160 shsESPREsperion Therapeutics$2.04-13.9%$2.32$0.70▼$3.40$448.88M0.897.04 million shs13.72 million shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-1.66%+3.96%-23.59%-15.38%-9.90%BMEABiomea Fusion-2.12%+11.73%-5.73%-34.28%-64.02%CRBPCorbus Pharmaceuticals+2.45%+7.37%-0.50%+65.57%+292.60%ESPREsperion Therapeutics+11.79%+20.30%-26.85%-9.89%+75.56%READ THIS – If You Missed Out On The AI Boom (Ad)Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.8664 of 5 stars4.53.00.00.00.02.50.6BMEABiomea Fusion1.5161 of 5 stars3.40.00.00.01.83.30.6CRBPCorbus Pharmaceuticals4.3173 of 5 stars3.52.00.04.72.43.30.6ESPREsperion Therapeutics3.8327 of 5 stars3.24.00.03.91.80.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon3.00Buy$14.43196.27% UpsideBMEABiomea Fusion2.75Moderate Buy$53.25381.03% UpsideCRBPCorbus Pharmaceuticals3.00Buy$53.0025.03% UpsideESPREsperion Therapeutics2.40Hold$9.33357.52% UpsideCurrent Analyst RatingsLatest CRBP, ESPR, BMEA, and ANNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2024CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $60.005/8/2024ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/7/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/3/2024BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.005/3/2024BMEABiomea FusionJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$14.00 ➝ $15.004/24/2024ANNXAnnexonCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight4/11/2024ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.004/10/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.004/3/2024ANNXAnnexonCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight4/3/2024BMEABiomea FusionOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.004/2/2024BMEABiomea FusionJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$51.00 ➝ $14.00(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/ABMEABiomea FusionN/AN/AN/AN/A$4.74 per shareN/ACRBPCorbus Pharmaceuticals$880K506.27N/AN/A($1.56) per share-27.17ESPREsperion Therapeutics$116.33M3.32N/AN/A($3.85) per share-0.53Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.78N/AN/AN/AN/A-66.54%-53.52%5/13/2024 (Estimated)BMEABiomea Fusion-$117.25M-$3.57N/AN/AN/AN/A-69.88%-60.44%7/29/2024 (Estimated)CRBPCorbus Pharmaceuticals-$44.60M-$10.37N/AN/AN/AN/A-920.31%-111.56%8/13/2024 (Estimated)ESPREsperion Therapeutics-$209.25M-$2.12N/A6.80N/A-179.87%N/A-91.62%8/6/2024 (Estimated)Latest CRBP, ESPR, BMEA, and ANNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023BMEABiomea FusionN/A-$0.98-$0.98-$0.98N/AN/A3/26/2024Q4 2023ANNXAnnexon-$0.45-$0.36+$0.09-$0.36N/AN/A3/12/2024Q4 2023CRBPCorbus Pharmaceuticals-$2.36-$1.81+$0.55-$1.81N/AN/A2/27/202412/31/2023ESPREsperion Therapeutics-$0.53-$0.50+$0.03-$0.50$26.84 million$32.25 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ABMEABiomea FusionN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A14.7214.72BMEABiomea FusionN/A5.845.84CRBPCorbus PharmaceuticalsN/A0.740.74ESPREsperion TherapeuticsN/A1.290.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ABMEABiomea Fusion96.72%CRBPCorbus Pharmaceuticals64.64%ESPREsperion Therapeutics47.39%Insider OwnershipCompanyInsider OwnershipANNXAnnexon19.11%BMEABiomea Fusion26.27%CRBPCorbus Pharmaceuticals4.00%ESPREsperion Therapeutics1.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon7191.14 million73.72 millionOptionableBMEABiomea Fusion10335.94 million26.50 millionOptionableCRBPCorbus Pharmaceuticals1910.51 million10.09 millionOptionableESPREsperion Therapeutics240189.40 million187.51 millionOptionableCRBP, ESPR, BMEA, and ANNX HeadlinesSourceHeadlineEsperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcriptmsn.com - May 8 at 4:10 PMEsperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenueszacks.com - May 8 at 1:20 PMEsperion Gains Buy Rating on Strong Sales Growth and Strategic Progressmarkets.businessinsider.com - May 8 at 11:09 AMEsperion Therapeutics (NASDAQ:ESPR) Given "Buy" Rating at HC Wainwrightmarketbeat.com - May 8 at 10:12 AMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Expected to Earn FY2026 Earnings of $1.44 Per Sharemarketbeat.com - May 8 at 7:36 AMEsperion Therapeutics (NASDAQ:ESPR) Given "Buy" Rating at Needham & Company LLCamericanbankingnews.com - May 8 at 5:52 AMEsperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...finance.yahoo.com - May 8 at 5:29 AMStock Traders Purchase High Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)americanbankingnews.com - May 8 at 1:16 AMEsperion Shares Jump on Strong 1Q Results Above Analyst Expectationsmarketwatch.com - May 7 at 7:29 PMEsperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% Increasefinance.yahoo.com - May 7 at 7:29 PMEsperion Therapeutics' (ESPR) Buy Rating Reaffirmed at Needham & Company LLCmarketbeat.com - May 7 at 2:35 PMEsperion Therapeutics Target of Unusually High Options Trading (NASDAQ:ESPR)marketbeat.com - May 7 at 12:31 PMESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024investorplace.com - May 7 at 12:03 PMWhy Is Esperion Therapeutics (ESPR) Stock Up 13% Today?investorplace.com - May 7 at 8:22 AMEsperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimateszacks.com - May 7 at 8:16 AMEsperion Therapeutics: Q1 Earnings Snapshotwashingtonpost.com - May 7 at 7:22 AMZacks Research Comments on Esperion Therapeutics, Inc.'s Q1 2026 Earnings (NASDAQ:ESPR)americanbankingnews.com - May 7 at 6:20 AMEsperion Reports First Quarter 2024 Financial Resultsglobenewswire.com - May 7 at 6:00 AMEsperion Therapeutics (ESPR) Set to Announce Earnings on Tuesdayamericanbankingnews.com - May 5 at 5:20 AMQ4 2025 Earnings Forecast for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Issued By Zacks Researchamericanbankingnews.com - May 2 at 2:38 AMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Down 6.6% in Aprilmarketbeat.com - May 1 at 9:25 PMEsperion Therapeutics, Inc. Common Stock (ESPR)nasdaq.com - May 1 at 7:43 PMEquities Analysts Set Expectations for Esperion Therapeutics, Inc.'s Q4 2025 Earnings (NASDAQ:ESPR)marketbeat.com - May 1 at 8:59 AMFY2025 EPS Estimates for Esperion Therapeutics, Inc. Decreased by Zacks Research (NASDAQ:ESPR)americanbankingnews.com - May 1 at 3:18 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAnnexonNASDAQ:ANNXAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Biomea FusionNASDAQ:BMEABiomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Corbus PharmaceuticalsNASDAQ:CRBPCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Esperion TherapeuticsNASDAQ:ESPREsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.